Loading news...
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Not all REIT dividends are sustainable. Overleverage, troubled assets, and high payout ratios are clear red flags. I highlight 3 popular REITs at high risk of cutting their dividend.
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of $3.144 per common share, representing a 3.6% increase over the annualized dividend amount of $3.036 per common share from the first quarter of 2025. The dividend is payable February 13, 2026 to stockholders.
Dividend investing is increasingly vital amid higher rates and inflation, offering passive income and wealth compounding for retirement. Anchoring a portfolio with quality dividend ETFs like SCHD, FDVV, or CGDV can provide reliable income and potential outperformance. Combining high dividend growers (e.g., V, MA, WM) with stable high-yielders (e.g., VZ, O, ADC, STWD) balances growth and income.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK'227), GSK's novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec.
REITs, after years of underperformance, are now attractively valued and poised for strong returns over the next 12–18 months. VICI Properties, NNN REIT, and Agree Realty offer robust yields, improving fundamentals, and raised guidance despite sector headwinds. VICI and NNN face tenant-specific risks, but their balance sheets, liquidity, and long-term growth prospects support a bullish outlook.
Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provide expected cash runway at least to 2028 Anticipated near-term catalysts include LOTIS-7 complete enrollment in first half of 2026 and LOTIS-5 Phase 3 topline data in second quarter 2026 Additional anticipated catalysts include full LOTIS-5 and LOTIS-7 results by end of 2026, with potential compendia inclusions in first half of 2027 and LOTIS-5 regulatory approvals to follow LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program. "During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 15, 2026, at 10:30 a.m.
CoreCap Advisors LLC boosted its holdings in shares of Agree Realty Corporation (NYSE: ADC) by 15.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,044 shares of the real estate investment trust's stock after buying an additional 7,186
Realty Income is a lumbering giant, but its 5.6% yield could be a cornerstone investment. Agree Realty competes with Realty Income, but it is much smaller, so its 4.3% yield comes with a growth kicker.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its fourth quarter and full year 2025 operating results after the market closes on Tuesday, February 10, 2026. A conference call to discuss the Company's operating results is scheduled for Wednesday, February 11, 2026, at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871 Intern.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ADC deployed $1.55B in 2025 across 338 retail net lease properties, strengthening investment-grade rent and setting up $1.25B-$1.5B plans for 2026.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Many REITs pay dividends on a monthly basis. Some offer up to 8% dividend yields. These are my favorite monthly-paying REITs.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced a summary of its investment activity in 2025, introduced investment guidance for 2026, and provided an update on its portfolio as well as its fourth quarter capital markets activity. 2025 Investment Activity Total real estate investment volume for 2025, inclusive of acquisition, development, and Developer Funding Platform (“DFP”) projects completed or under construction, amounted to a total o.
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Crescent partner Kelun-Biotech receives IND approval for CR-003 (SKB105) by NMPA of China Four clinical trials across portfolio expected to initiate in 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced regulatory clearances of Investigational New Drug (IND) applications for CR-001, a PD-1 x VEGF bispecific antibody, and CR-003, an integrin beta-6 (ITGB6)-targeted antibody drug-conjugate (ADC), both being developed for the treatment of advanced solid tumors.
LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company's common shares to a new employee on January 2, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.